Orexo initiates new study of OX640 in participants with allergic rhinitis

OX640 is an intranasal rescue medication for the treatment of severe allergic reactions (incl. anaphylaxis) with powder-based epinephrine.OX640 is based on Orexo´s proprietary drug delivery platform, AmorphOX®, and has demonstrated positive data in a phase 1 clinical study in healthy volunteers.The new study will investigate the performance of OX640 in participants with allergic rhinitis.View original content:https://www.prnewswire.co.uk/news-releases/orexo-initiates-new-study-of-ox640-in-participants-with-allergic-rhinitis-302287325.html